• Redox-Responsive Peptide Coacervates for mRNA Delivery

  2026-09-27

  The study introduces HBpep-SS4, a single-component peptide coacervate whose cysteine-encoded disulfide bonds support stable RNA encapsulation and glutathione-responsive release. Its reported activity across RNA formats and genome-editing targets highlights a potential alternative delivery strategy, while leaving important questions about in vivo performance and comparative safety open.

• Dihydrotestosterone (DHT): Signaling & Research Use

  2026-09-26

  Dihydrotestosterone (DHT) is an endogenous androgen and potent androgen receptor agonist used to investigate receptor signaling in defined experimental models. Product information summarizes effects in androgen receptor-positive bladder cancer cells and SOD1-G93A mice, while the supplied evidence does not establish clinical efficacy or fully specify experimental protocols.

• Pam3CSK4 at the Neuro-Immune Interface

  2026-09-25

  How Pam3CSK4 can help translational researchers interrogate TLR1/2-driven innate immune activation—and place that response in the context of emerging neural control of inflammation.

• Sulfisomidine: From Degradation to Assay Decisions

  2026-09-25

  Sulfisomidine (sulfamethin) is a useful model for studying both pharmaceutical transformation and assay interpretation. Learn why parent-compound loss is not the same as detoxification, how real-water matrices change UV-Fenton results, and how to plan more informative experiments.

• HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody

  2026-09-24

  Translate neuroblastoma photodynamic-therapy findings into practical fluorescence-assay choices with a bright, red-emitting rabbit IgG detector. This guide distinguishes what the study measured from what a secondary antibody can help researchers measure next—and shows how to optimize staining across imaging, tissue, and flow workflows.

• Lamotrigine in BBB and Sodium-Channel Research

  2026-09-24

  Use Lamotrigine to connect sodium-channel pharmacology with a disciplined, transporter-aware CNS assay workflow—without mistaking barrier passage for target engagement. A recent LLC-PK1-MDR1 study offers practical benchmarks for permeability, efflux, and low-recovery troubleshooting.

• EZH2i and 5-Azacytidine Restore Immunity in GBM

  2026-09-23

  A 2025 study reports that PTEN deficiency suppresses the ERV–MAVS–type I interferon pathway in glioblastoma, helping maintain an immunosuppressive tumor microenvironment. In the study, 5-azacytidine alone did not overcome this barrier, whereas combining it with EZH2 inhibition reduced H3K27me3, promoted endogenous retrovirus expression, and restored antiviral signaling linked to antitumor immunity.

• Luminescent ATP Cell Viability Assay Kit I for Ferroptosis

  2026-09-23

  Rapid ATP-based luminescence helps distinguish treatment-driven loss of viable cells from slower metabolic changes in ferroptosis experiments. The ready-to-use, no-wash workflow supports sensitive cytotoxicity screening across a reported 10–30,000-cell linear range.

• Diuron: From Photosynthesis to Kidney Risk

  2026-09-22

  Diuron is more than a benchmark photosynthesis inhibitor: it is a useful model for connecting herbicide mechanism, renal toxicology, and assay design. This evidence-focused guide translates recent JAK2/STAT1 findings into practical decisions for plant biology research and environmental toxicology.

• Dabigatran Etexilate: Assay-First Mechanism

  2026-09-22

  Dabigatran etexilate is an oral prodrug that enables precise study of direct thrombin inhibition and coagulation cascade modulation. This assay-first guide connects prodrug activation, pharmacodynamic readouts, experimental controls, and research-grade handling decisions.

• (-)-JQ1 Controls for BET and PDA Assays

  2026-09-21

  (-)-JQ1 is a mechanistically matched inactive control that helps separate BET-dependent effects from vehicle, stereochemistry, and general cytotoxicity. This guide translates a pancreatic cancer screening study into practical workflows for epigenetics research, BRD4 validation, and combination assays.

• Macrophage EP4 Deficiency in Atherosclerosis

  2026-09-21

  The reference study identifies macrophage EP4 loss as a driver of atherosclerosis progression, linking enhanced CD36-dependent lipid uptake with foam cell formation and M1-skewed inflammation. Its combination of myeloid-specific mouse genetics, oxLDL-stimulated macrophages, transcriptomics, proteomics, and molecular validation provides a useful framework for studying how prostaglandin signaling affects plaque biology.

• High-Throughput BBB Model and Lysosomal Trapping

  2026-09-20

  Hu and colleagues developed a Transwell blood-brain barrier surrogate that combines LLC-PK1-MOCK and LLC-PK1-MDR1 cells with a correction for lysosomal drug trapping. Across 41 compounds, the model linked in vitro permeability with unbound brain distribution and provided a practical framework for prioritizing CNS candidates before extensive in vivo testing.

• Risedronate Sodium: Workflows for Bone Research

  2026-09-19

  Risedronate Sodium is a practical FPP synthase inhibitor for connecting osteoclast biology with delivery-focused bone and pulmonary studies. This guide translates its aqueous handling requirements, concentration range, and nanotransfersome–microneedle evidence into reproducible workflows, assay choices, and troubleshooting decisions.

• β-Galactosidase Reporter Assay Kit: Cross-Kingdom

  2026-09-18

  Explore how a β-Galactosidase Reporter Assay Kit can convert promoter activity into a practical, comparable readout for synthetic biology. This guide connects reporter kinetics with the latest cross-kingdom promoter design in Escherichia coli and Saccharomyces cerevisiae.

8493 records 1/567 page Next 12345 下5页 Last page